NO20035087D0 - Anvendelse av HMG fragment som anti-inflammatoriske midler - Google Patents
Anvendelse av HMG fragment som anti-inflammatoriske midlerInfo
- Publication number
- NO20035087D0 NO20035087D0 NO20035087A NO20035087A NO20035087D0 NO 20035087 D0 NO20035087 D0 NO 20035087D0 NO 20035087 A NO20035087 A NO 20035087A NO 20035087 A NO20035087 A NO 20035087A NO 20035087 D0 NO20035087 D0 NO 20035087D0
- Authority
- NO
- Norway
- Prior art keywords
- inflammatory agents
- hmg
- fragment
- hmg fragment
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29103401P | 2001-05-15 | 2001-05-15 | |
PCT/US2002/015329 WO2002092004A2 (en) | 2001-05-15 | 2002-05-15 | Use of hmg fragment as anti-inflammatory agents |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20035087D0 true NO20035087D0 (no) | 2003-11-14 |
NO20035087L NO20035087L (no) | 2003-12-09 |
Family
ID=23118552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20035087A NO20035087L (no) | 2001-05-15 | 2003-11-14 | Anvendelse av HMG fragment som anti-inflammatoriske midler |
Country Status (18)
Country | Link |
---|---|
US (2) | US20030060410A1 (no) |
EP (1) | EP1392844A4 (no) |
JP (1) | JP2005512507A (no) |
KR (1) | KR20040018370A (no) |
CN (1) | CN100447154C (no) |
AU (1) | AU2002309829B2 (no) |
BR (1) | BR0209689A (no) |
CA (1) | CA2447576C (no) |
CZ (1) | CZ20033402A3 (no) |
HU (1) | HUP0500042A3 (no) |
IL (3) | IL158643A0 (no) |
IS (1) | IS7037A (no) |
MX (1) | MXPA03010449A (no) |
NO (1) | NO20035087L (no) |
NZ (1) | NZ529423A (no) |
PL (1) | PL367132A1 (no) |
SK (1) | SK15422003A3 (no) |
WO (1) | WO2002092004A2 (no) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7151082B2 (en) | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US7754217B2 (en) * | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
CA2491321A1 (en) * | 2002-07-03 | 2004-01-15 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
US20040141948A1 (en) * | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
US20060121047A1 (en) * | 2002-11-20 | 2006-06-08 | Tracey Kevin J | Use of hmgb polypetides for increasing immune responses |
US20040156851A1 (en) * | 2002-11-20 | 2004-08-12 | Critical Therapeutics, Inc. | HMGB1 combination therapies |
JP4750421B2 (ja) * | 2002-12-06 | 2011-08-17 | ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト | α7受容体結合コリン作動性アゴニストを用いる炎症の阻害 |
US20090069227A9 (en) * | 2003-04-29 | 2009-03-12 | Capogrossi Maurizio C | Use of HMGB1 to promote stem cell migration and/or proliferation |
US7696169B2 (en) * | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
WO2005025604A2 (en) * | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
CA2538763C (en) * | 2003-09-11 | 2015-05-05 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
EP1768698A4 (en) | 2004-06-17 | 2009-01-28 | Medimmune Inc | IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES |
US7470521B2 (en) | 2004-07-20 | 2008-12-30 | Critical Therapeutics, Inc. | RAGE protein derivatives |
WO2006012373A2 (en) * | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
WO2006024547A2 (en) * | 2004-09-03 | 2006-03-09 | Creabilis Therapeutics S.P.A. | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
CA2585043A1 (en) | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
EP1899376A2 (en) | 2005-06-16 | 2008-03-19 | The Feinstein Institute for Medical Research | Antibodies against hmgb1 and fragments thereof |
EP1909834A2 (en) * | 2005-07-18 | 2008-04-16 | Critical Therapeutics, Inc. | Use of hmgb1 antagonists for the treatment of inflammatory skin conditions |
JP3876325B1 (ja) | 2005-10-24 | 2007-01-31 | 国立大学法人 岡山大学 | 脳梗塞抑制剤 |
US20100172909A1 (en) * | 2005-10-24 | 2010-07-08 | Masahiro Nishibori | Cerebral edema suppressant |
JP2009517404A (ja) * | 2005-11-28 | 2009-04-30 | メディミューン,エルエルシー | Hmgb1および/またはrageのアンタゴニストならびにその使用方法 |
WO2007130725A2 (en) * | 2006-02-06 | 2007-11-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of hmgb1 for protection against ischemia reperfusion injury |
JPWO2007102410A1 (ja) * | 2006-02-24 | 2009-07-23 | 国立大学法人金沢大学 | Rageポリペプチドの新規用途 |
JP3882090B1 (ja) | 2006-05-19 | 2007-02-14 | 国立大学法人 岡山大学 | 脳血管攣縮抑制剤 |
MX2009002820A (es) | 2006-09-15 | 2009-06-04 | Creabilis Therapeutics Spa | Conjugados polimericos de box-a de hmgb1 y variantes de box-a de hmgb1. |
ATE505205T1 (de) * | 2006-09-15 | 2011-04-15 | Creabilis Therapeutics Spa | Polymerkonjugate von box-a von hmgb1 und box-a- varianten von hmgb1 |
WO2008099917A1 (ja) * | 2007-02-15 | 2008-08-21 | Fukuoka University | 抗hmgb-1抗体を含む臓器移植拒絶抑制剤 |
TW200900077A (en) | 2007-02-15 | 2009-01-01 | Univ Kyushu Nat Univ Corp | Therapeutic agent for interstitial pulmonary disease comprising anti-HMGB-1 antibody |
TW200902063A (en) | 2007-02-15 | 2009-01-16 | Univ Kumamoto | Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient |
JP5676253B2 (ja) | 2008-04-30 | 2015-02-25 | 株式会社ジェノミックス | 生体内機能的細胞の高効率採取法 |
RU2519714C2 (ru) | 2008-04-30 | 2014-06-20 | Дженомикс Ко., Лтд. | Средство для вовлечения происходящей из костного мозга плюрипотентной стволовой клетки в периферический кровоток |
JP5467313B2 (ja) | 2009-09-28 | 2014-04-09 | 国立大学法人 岡山大学 | アテローム動脈硬化抑制剤 |
KR20120135190A (ko) | 2009-10-28 | 2012-12-12 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제 |
CA2787661C (en) | 2010-01-21 | 2021-10-12 | The Board Of Trustees Of The University Of Arkansas | Vaccine vectors and methods of enhancing immune responses |
EP3556397A1 (en) | 2010-06-09 | 2019-10-23 | The Board of Trustees of the University of Arkansas | Vaccine and methods to reduce campylobacter infection |
US20120128701A1 (en) * | 2010-09-09 | 2012-05-24 | Nationwide Children's Hospital, Inc. | Compositions and methods for the removal of biofilms |
EP2703487B1 (en) | 2011-04-26 | 2018-06-27 | Genomix Co., Ltd. | Peptide for inducing regeneration of tissue and use thereof |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
US9244074B2 (en) * | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
SG11201503236RA (en) * | 2012-10-25 | 2015-06-29 | Genomix Co Ltd | Novel method for treating cardiac infarction using hmgb1 fragment |
CN104955470B (zh) * | 2012-10-25 | 2017-06-16 | 吉诺米克斯股份有限公司 | 利用了hmgb1片段的针对脊髄损伤的新型治疗方法 |
PL2956165T3 (pl) | 2013-02-14 | 2020-04-30 | The Board Of Trustees Of The University Of Arkansas | Kompozycje i sposoby wzmacniania odpowiedzi immunologicznych na Eimeria lub ograniczania infekcji Eimeria |
EA033538B1 (ru) | 2013-03-15 | 2019-10-31 | Univ Arkansas | Композиции и способы усиления иммунного ответа на кишечные патогены |
US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
US9745366B2 (en) | 2013-09-23 | 2017-08-29 | University Of Southern California | Compositions and methods for the prevention of microbial infections |
US10233234B2 (en) | 2014-01-13 | 2019-03-19 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
US11248040B2 (en) | 2013-09-26 | 2022-02-15 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
GB201508337D0 (en) | 2015-05-15 | 2015-06-24 | Hmgbiotech S R L | Novel peptides |
JP2018528763A (ja) | 2015-07-31 | 2018-10-04 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | バイオフィルムの除去のためのペプチドおよび抗体 |
US10682398B2 (en) | 2016-05-03 | 2020-06-16 | The Texas A&M University System | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same |
CA3051825A1 (en) | 2017-01-27 | 2018-08-02 | StemRIM Inc. | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure |
AU2018236271B2 (en) | 2017-03-15 | 2023-12-21 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
CN113203857B (zh) * | 2021-05-06 | 2021-12-31 | 上海奕检医学检验实验室有限公司 | 一种肿瘤诊断试剂盒 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US53841A (en) * | 1866-04-10 | Improvement in measuring-funnels | ||
US60410A (en) * | 1866-12-11 | newman | ||
US144201A (en) * | 1873-11-04 | Improvement in volute springs | ||
JPS62166897A (ja) * | 1986-01-20 | 1987-07-23 | Toyo Soda Mfg Co Ltd | 核内非ヒストン蛋白質に対するモノクロ−ナル抗体 |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
GB9217316D0 (en) * | 1992-08-14 | 1992-09-30 | Ludwig Inst Cancer Res | Schwann cell mitogenic factor,its preparation and use |
JP3472048B2 (ja) * | 1995-10-09 | 2003-12-02 | 鐘淵化学工業株式会社 | 自己免疫疾患の診断薬 |
US6323329B1 (en) * | 1995-12-21 | 2001-11-27 | Jorn Bullerdiek | Nucleic acid sequences of genes encoding high mobility group proteins |
US6171779B1 (en) * | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
US6720472B2 (en) * | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
CA2262443A1 (en) * | 1996-07-17 | 1998-01-22 | Kaneka Corporation | Diagnostic drugs for autoimmune diseases |
US20030032090A1 (en) * | 1997-05-07 | 2003-02-13 | Schering Corporation, A New Jersey Corporation | Human receptor proteins; related reagents and methods |
US20030027260A1 (en) * | 1997-10-17 | 2003-02-06 | Genentech, Inc. | Human Toll homologues |
US6228642B1 (en) | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US7151082B2 (en) * | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
US6677321B1 (en) * | 1999-12-09 | 2004-01-13 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
AU2001266787A1 (en) * | 2000-06-07 | 2002-01-08 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
US7754217B2 (en) * | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
US20030032674A1 (en) * | 2001-08-13 | 2003-02-13 | Hwang Daniel H. | Use of unsaturated fatty acids to treat severe inflammatory diseases |
JP2003052763A (ja) * | 2001-08-16 | 2003-02-25 | Paramount Bed Co Ltd | ベッドにおける側柵 |
-
2002
- 2002-05-15 NZ NZ529423A patent/NZ529423A/en not_active IP Right Cessation
- 2002-05-15 JP JP2002588923A patent/JP2005512507A/ja active Pending
- 2002-05-15 HU HU0500042A patent/HUP0500042A3/hu unknown
- 2002-05-15 CA CA2447576A patent/CA2447576C/en not_active Expired - Fee Related
- 2002-05-15 US US10/147,447 patent/US20030060410A1/en not_active Abandoned
- 2002-05-15 PL PL02367132A patent/PL367132A1/xx not_active Application Discontinuation
- 2002-05-15 KR KR10-2003-7014914A patent/KR20040018370A/ko not_active Application Discontinuation
- 2002-05-15 WO PCT/US2002/015329 patent/WO2002092004A2/en active Application Filing
- 2002-05-15 AU AU2002309829A patent/AU2002309829B2/en not_active Ceased
- 2002-05-15 BR BR0209689-7A patent/BR0209689A/pt not_active Application Discontinuation
- 2002-05-15 MX MXPA03010449A patent/MXPA03010449A/es active IP Right Grant
- 2002-05-15 CN CNB028120388A patent/CN100447154C/zh not_active Expired - Fee Related
- 2002-05-15 SK SK1542-2003A patent/SK15422003A3/sk unknown
- 2002-05-15 EP EP02736852A patent/EP1392844A4/en not_active Withdrawn
- 2002-05-15 CZ CZ20033402A patent/CZ20033402A3/cs unknown
- 2002-05-15 IL IL15864302A patent/IL158643A0/xx unknown
-
2003
- 2003-06-06 US US10/456,949 patent/US20040005316A1/en not_active Abandoned
- 2003-10-28 IL IL158643A patent/IL158643A/en not_active IP Right Cessation
- 2003-11-14 NO NO20035087A patent/NO20035087L/no not_active Application Discontinuation
- 2003-11-14 IS IS7037A patent/IS7037A/is unknown
-
2010
- 2010-10-24 IL IL208892A patent/IL208892A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20040005316A1 (en) | 2004-01-08 |
CA2447576A1 (en) | 2002-11-21 |
JP2005512507A (ja) | 2005-05-12 |
WO2002092004A8 (en) | 2003-11-27 |
HUP0500042A2 (hu) | 2005-03-29 |
MXPA03010449A (es) | 2004-12-06 |
SK15422003A3 (sk) | 2005-01-03 |
IS7037A (is) | 2003-11-14 |
CN100447154C (zh) | 2008-12-31 |
AU2002309829B2 (en) | 2007-08-23 |
HUP0500042A3 (en) | 2010-01-28 |
IL208892A (en) | 2015-04-30 |
WO2002092004A3 (en) | 2003-10-09 |
NO20035087L (no) | 2003-12-09 |
CA2447576C (en) | 2014-04-08 |
IL208892A0 (en) | 2011-07-31 |
CZ20033402A3 (cs) | 2004-10-13 |
EP1392844A2 (en) | 2004-03-03 |
PL367132A1 (en) | 2005-02-21 |
EP1392844A4 (en) | 2006-09-06 |
BR0209689A (pt) | 2006-02-07 |
NZ529423A (en) | 2008-10-31 |
IL158643A0 (en) | 2004-05-12 |
CN1516739A (zh) | 2004-07-28 |
IL158643A (en) | 2010-12-30 |
WO2002092004A2 (en) | 2002-11-21 |
KR20040018370A (ko) | 2004-03-03 |
US20030060410A1 (en) | 2003-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20035087D0 (no) | Anvendelse av HMG fragment som anti-inflammatoriske midler | |
NO20041339D0 (no) | Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler | |
ATE309997T1 (de) | Entzündungshemmende benzimidazolverbindungen | |
NO20042680L (no) | Fremgangsmater for fremstilling av O-demetylvenflaxine | |
NO20033593D0 (no) | Kinazoliner som MMP-13 inhibitorer | |
IS6971A (is) | Ný efnasambönd | |
NO20014412D0 (no) | Forbindelser nyttige som anti-inflammatoriske midler | |
NO20044916L (no) | Preparater av sulfinylacetamid | |
NO20033205D0 (no) | Terapeutiske kromanforbindelser | |
DE60324806D1 (de) | Entzündungshemmende di- und trifluortriazolopyridin-verbindungen | |
FI20011889A0 (fi) | Menetelmä ksylitolin valmistamiseksi | |
NO20041968L (no) | Anvendelse av cystationin | |
EE200300434A (et) | Farmatseutiliselt toimivate ühendite kasutamine | |
FR2843451B1 (fr) | Fronde du type lance-pierres | |
NO20025765L (no) | Kombinasjonssett for behandling av malaria | |
FI20012242A0 (fi) | Uudet farmaseuttiset yhdisteet | |
SE0101239D0 (sv) | Pharmaceutically useful compounds | |
ITMI20011705A0 (it) | Antiinfiammatori non asteroidei per il trattamento per via rettale dioligastenospermia | |
FI20010467A (fi) | Purkauslamppu | |
SE0100007D0 (sv) | Therapeutic compounds | |
SE0100009D0 (sv) | Therapeutic compounds | |
SE0100006D0 (sv) | Therapeutic compounds | |
SE0100008D0 (sv) | Therapeutic compounds | |
SE0102056D0 (sv) | New Compounds | |
SE0100629D0 (sv) | New compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |